fbpx
Wikipedia

Insulin degludec/insulin aspart

January 01, 1970

Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus.[6][7][8][9] It contains insulin degludec and insulin aspart.[6] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.[6]

Insulin degludec/insulin aspart
Combination of
Insulin degludecLong-acting human insulin analog
Insulin aspartFast-acting human insulin analog
Clinical data
Trade namesRyzodeg
AHFS/Drugs.comProfessional Drug Facts
Pregnancy
category
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
CAS Number
  • 1392491-77-8
KEGG
  • D10570

The most frequently reported side effect is hypoglycemia (low blood glucose levels).[6]

It was approved for medical use in the European Union in January 2013,[6] and in Australia in November 2017.[2]

Medical uses edit

Insulin degludec/insulin aspart is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of two years.[6]

Insulin degludec and insulin aspart are slightly different from human insulin.[6] The differences mean that insulin degludec is absorbed more slowly by the body.[6] This means it has a long duration of action.[6] Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action.[6]

References edit

  1. ^ "Insulin aspart / insulin degludec (Ryzodeg 70/30) Use During Pregnancy". Drugs.com. 30 June 2020. Retrieved 26 July 2020.
  2. ^ a b c "Ryzodeg 70/30 FlexTouch and Penfill (insulin degludec/insulin aspart) solution" (PDF). Novo Nordisk Pharmaceuticals Pty Ltd.
  3. ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
  4. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  5. ^ Australian Public Assessment Report for insulin degludec (rys)/insulin aspart (rys) (PDF) (Report). Therapeutic Goods Administration (TGA).
  6. ^ a b c d e f g h i j k "Ryzodeg EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 18 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ Kalra S, Atkin S, Cervera A, Das AK, Demir O, Demir T, Fariduddin M, Vo KT, Ku BJ, Kumar A, Latif ZA, Malek R, Matawaran BJ, Mehta R, Tran NQ, Panelo A, Ruder S, Saldana JR, Shaikh KA, Shakya A, Shrestha D, Unnikrishnan AG (July 2018). "Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp)". Advances in Therapy. 35 (7): 928–936. doi:10.1007/s12325-018-0712-2. PMID 29796928. S2CID 85473292.
  8. ^ Mehta R, Chen R, Hirose T, John M, Kok A, Lehmann R, Unnikrishnan AG, Yavuz DG, Fulcher G (November 2020). "Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines". Diabetes, Obesity & Metabolism. 22 (11): 1961–1975. doi:10.1111/dom.14128. PMC 7689716. PMID 32618405.
  9. ^ Demir T, Turan S, Unluhizarci K, Topaloglu O, Tukek T, Gogas Yavuz D (2021). "Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns". Frontiers in Endocrinology. 12: 616514. doi:10.3389/fendo.2021.616514. PMC 7996092. PMID 33776914.


 

This article about an endocrine, nutritional, or metabolic disease is a stub. You can help Wikipedia by expanding it.

January 01, 1970
insulin, degludec, insulin, aspart, sold, under, brand, name, ryzodeg, fixed, dose, combination, medication, treatment, diabetes, mellitus, contains, insulin, degludec, insulin, aspart, given, injection, under, skin, abdominal, wall, front, waist, upper, thigh. Insulin degludec insulin aspart sold under the brand name Ryzodeg is a fixed dose combination medication for the treatment of diabetes mellitus 6 7 8 9 It contains insulin degludec and insulin aspart 6 It is given as an injection under the skin in the abdominal wall at the front of the waist upper arm or thigh 6 Insulin degludec insulin aspartCombination ofInsulin degludecLong acting human insulin analogInsulin aspartFast acting human insulin analogClinical dataTrade namesRyzodegAHFS Drugs comProfessional Drug FactsPregnancycategoryAU B3 1 2 Routes ofadministrationSubcutaneous injectionATC codeA10AD06 WHO Legal statusLegal statusAU S4 Prescription only 2 3 4 5 EU Rx only 6 IdentifiersCAS Number1392491 77 8KEGGD10570 The most frequently reported side effect is hypoglycemia low blood glucose levels 6 It was approved for medical use in the European Union in January 2013 6 and in Australia in November 2017 2 Contents 1 Medical uses 2 ReferencesMedical uses editInsulin degludec insulin aspart is indicated for the treatment of diabetes mellitus in adults adolescents and children from the age of two years 6 Insulin degludec and insulin aspart are slightly different from human insulin 6 The differences mean that insulin degludec is absorbed more slowly by the body 6 This means it has a long duration of action 6 Meanwhile insulin aspart is absorbed faster by the body than human insulin and therefore it starts to work as soon as it is injected and has a short duration of action 6 References edit Insulin aspart insulin degludec Ryzodeg 70 30 Use During Pregnancy Drugs com 30 June 2020 Retrieved 26 July 2020 a b c Ryzodeg 70 30 FlexTouch and Penfill insulin degludec insulin aspart solution PDF Novo Nordisk Pharmaceuticals Pty Ltd Prescription medicines registration of new chemical entities in Australia 2017 Therapeutic Goods Administration TGA 21 June 2022 Retrieved 9 April 2023 Prescription medicines and biologicals TGA annual summary 2017 Therapeutic Goods Administration TGA 21 June 2022 Retrieved 31 March 2024 Australian Public Assessment Report for insulin degludec rys insulin aspart rys PDF Report Therapeutic Goods Administration TGA a b c d e f g h i j k Ryzodeg EPAR European Medicines Agency EMA 17 September 2018 Retrieved 18 July 2020 Text was copied from this source which is c European Medicines Agency Reproduction is authorized provided the source is acknowledged Kalra S Atkin S Cervera A Das AK Demir O Demir T Fariduddin M Vo KT Ku BJ Kumar A Latif ZA Malek R Matawaran BJ Mehta R Tran NQ Panelo A Ruder S Saldana JR Shaikh KA Shakya A Shrestha D Unnikrishnan AG July 2018 Multinational Consensus Insulin Initiation with Insulin Degludec Aspart IDegAsp Advances in Therapy 35 7 928 936 doi 10 1007 s12325 018 0712 2 PMID 29796928 S2CID 85473292 Mehta R Chen R Hirose T John M Kok A Lehmann R Unnikrishnan AG Yavuz DG Fulcher G November 2020 Practical use of insulin degludec insulin aspart in a multinational setting beyond the guidelines Diabetes Obesity amp Metabolism 22 11 1961 1975 doi 10 1111 dom 14128 PMC 7689716 PMID 32618405 Demir T Turan S Unluhizarci K Topaloglu O Tukek T Gogas Yavuz D 2021 Use of Insulin Degludec Insulin Aspart in the Management of Diabetes Mellitus Expert Panel Recommendations on Appropriate Practice Patterns Frontiers in Endocrinology 12 616514 doi 10 3389 fendo 2021 616514 PMC 7996092 PMID 33776914 Portal nbsp Medicine nbsp This article about an endocrine nutritional or metabolic disease is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Insulin degludec insulin aspart amp oldid 1216457086, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.